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Lifelong multilineage hematopoiesis critically depends on rare hematopoietic stem cells
(HSCs) that reside in the hypoxic bone marrow microenvironment. Although the role of the
canonical oxygen sensor hypoxia-inducible factor prolyl hydroxylase has been investigated
extensively in hematopoiesis, the functional significance of other members of the
2-oxoglutarate (2-OG)-dependent protein hydroxylase family of enzymes remains poorly
defined in HSC biology and multilineage hematopoiesis. Here, by using hematopoietic-
specific conditional gene deletion, we reveal that the 2-OG–dependent protein hydroxylase
JMJD6 is essential for short- and long-term maintenance of the HSC pool and multilineage
hematopoiesis. Additionally, upon hematopoietic injury, Jmjd6-deficient HSCs display
a striking failure to expand and regenerate the hematopoietic system. Moreover, HSCs
lacking Jmjd6 lose multilineage reconstitution potential and self-renewal capacity upon
serial transplantation. At the molecular level, we found that JMJD6 functions to repress
multiple processes whose downregulation is essential for HSC integrity, including
mitochondrial oxidative phosphorylation (OXPHOS), protein synthesis, p53 stabilization,
cell cycle checkpoint progression, and mTORC1 signaling. Indeed, Jmjd6-deficient
primitive hematopoietic cells display elevated basal and maximal mitochondrial
respiration rates and increased reactive oxygen species (ROS), prerequisites for HSC
failure. Notably, an antioxidant, N-acetyl-L-cysteine, rescued HSC and lymphoid
progenitor cell depletion, indicating a causal impact of OXPHOS-mediated ROS
generation upon Jmjd6 deletion. Thus, JMJD6 promotes HSC maintenance and
multilineage differentiation potential by suppressing fundamental pathways whose
activation is detrimental for HSC function.
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Introduction
Multilineage hematopoiesis relies on hematopoietic stem cells (HSCs)
residing within the hypoxic bone marrow (BM) microenvironment.1
Cellular responses to oxygen are predominantly mediated by
hypoxia-inducible factor-a prolyl hydroxylase domain enzymes
(PHDs), namely PHD1-3, which belong to the 2-oxoglutrate (2-OG)–
dependent protein hydroxylase family.2 Indeed, conditional Phd2
deletion compromises HSC maintenance,3 and pharmacological
PHD inhibition promotes HSC quiescence and enhances their
mobilization from the BM.4,5 Notably, however, the functional
significance of other 2-OG–dependent protein hydroxylases in
HSCs and multilineage hematopoiesis remains elusive.
Here, we focus on JMJD6, a predominantly, though not exclusively,
nuclear 2-OG–dependent protein hydroxylase with promiscuous
substrate specificity.2,6,7 JMJD6-catalyzed protein hydroxylation
is reported to be involved in the hypoxic response,8-10 RNA
splicing,11,12 and regulation of gene transcription.13,14 JMJD6
has an essential function in embryonic development, with Jmjd6-null
mice displaying perinatal lethality due to developmental defects of
multiple organs, including kidney, intestine, liver, heart, and lungs.15,16
Furthermore, JMJD6 has been identified as a key regulator of
tumorigenesis.7,17-19 However, the physiological significance of
JMJD6 in normal adult tissue function remains poorly understood.
In our study, we used hematopoietic-specific conditional genetics
to reveal JMJD6 as a fundamental regulator of adult HSC biology
during unperturbed hematopoiesis, as well as upon hematopoietic
injury and serial transplantation. Notably, we found that JMJD6
suppresses multiple pathways whose excessive activation is
detrimental to normal hematopoiesis, including oxidative phosphor-




All mice were on a C57BL/6 background, Vav-iCre mice20 have
been described previously. The generation of Jmjd6fl mice is described
in supplemental Figure 1. All transgenic and knockout mice were
CD45.21. Congenic recipient mice were CD45.11/CD45.21.
All experiments involving mice were performed under University
of Edinburgh and Queen Mary University of London Veterinary
oversight with UK Home Office authorization. Treatment groups
were randomized within boxes of littermates.
Flow cytometry
Peripheral blood (PB), BM, and splenic cells were prepared and
analyzed as described previously.21-28 Hematopoietic stem and
progenitor cell staining began with incubation with Fc block, followed
by biotin-conjugated anti-lineage marker antibodies (anti-CD4, anti-
CD5, anti-CD8a, anti-CD11b, anti-B220, anti–Gr-1, and anti-Ter119),
allophycocyanin (APC)-conjugated anti–c-Kit, APC-Cy7–conjugated
anti–Sca-1, phycoerythrin (PE)-conjugated anti-CD48, and PE-
Cy7–conjugated anti-CD150 antibodies. Biotin-conjugated line-
age markers were then stained with PerCP-conjugated streptavidin.
For PB and differentiated cell analysis, cells were stained with
PerCP-conjugated anti-B220, APC-Cy7–conjugated anti-CD19, APC-
conjugated anti-CD11b, PE-Cy7–conjugated anti–Gr-1, PE-conjugated
anti-CD8, and PE-conjugated anti-CD4 antibodies. To distinguish
CD45.2 chimerism in transplantation experiments, fluorescein
isothiocyanate–conjugated anti-CD45.1 and Pacific Blue–conjugated
anti-CD45.2 antibodies were used. Flow cytometry analyses were
performed using a LSRFortessa (BD). Cell sorting was performed
on a FACSAria Fusion (BD).
Cell cycle analysis
BM samples were enriched for c-Kit1 cells and stained for surface
markers, as described above, followed by fixation and permeabiliza-
tion using Fixation/Permeabilization solution (BD Biosciences).
The cells were then stained with PE-conjugated anti-Ki67 antibody
(BioLegend). 49,6-Diamidino-2-phenylindole (DAPI) was added before
sample analysis.
Syngeneic transplantation assays
Transplant recipient CD45.11/CD45.21 mice were lethally irradi-
ated with 2 5.5-Gy doses administered $4 hours apart, at an
average rate of 0.58 Gy/min, using a 137Cs Gammacell 40
irradiator. For primary transplantations, lethally irradiated recipient
CD45.11/CD45.21mice were injected IV with 100 Lin2Sca-11c-Kit1
(LSK)CD482CD1501 HSCs and 200000 support CD45.11 unfrac-
tionated BM cells. For secondary transplantations, lethally irradiated
recipient CD45.11/CD45.21 mice were injected IV with 4 3 106
unfractionated CD45.21 BM cells from primary recipients and
200 000 support CD45.11 unfractionated BM cells. All recipient
mice were analyzed at 16 weeks posttransplantation.
CD117 (c-Kit) enrichment
Enrichment for CD117 (c-Kit)–expressing cells was performed
using CD117 MicroBeads and LS columns (Miltenyi Biotec),
according to the manufacturer’s instructions.
CFC assays
Colony-forming cell (CFC) assays were performed using MethoCult
(M3434; STEMCELL Technologies). Two replicates were used
per group in each experiment. For CFC assay experiments
using N-acetyl-L-cysteine (NAC) (Sigma), NAC was dissolved in
phosphate-buffered saline (PBS) and added at a concentration of
5 mM before plating.
Administration of 5-FU
Mice received 250 mg/kg of 5-fluorouracil (5-FU) via 1 IV injection.
PBS was injected via 1 IV injection for control animals.
ROS analysis
BM cells were enriched for c-Kit1 cells and stained for ROS levels
using CellROX reagent (Invitrogen), according to the manufacturer’s
instructions.
Administration of NAC
Mice received 100 mg/kg NAC via daily intraperitoneal injection,
as well as in drinking water (1 mg/mL) for the duration of the
experiment. The water bottle containing NAC was changed twice
per week.
Oxygen-consumption assays
Oxygen-consumption rates (OCRs) were measured using a
Seahorse XF-24 analyzer (Seahorse Bioscience) and an XF
Cell Mito Stress Test kit, as previously described.22 c-Kit1 cells
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Figure 1. JMJD6 is required for steady-state multilineage hematopoiesis, whereas Jmjd6-deficient HSCs have a normal apoptotic and cell cycle status. (A)
Relative levels of Jmjd6 messenger RNA (normalized to Hprt) in cells isolated from BM of 8- to 12-week-old adult C57BL/6 mice: LSKCD482CD1501 HSCs, LSKCD482
CD1502 MPPs, primitive HPCs (ie, LSKCD481CD1502 HPC-1 and LSKCD481CD1501 HPC-2 populations), LSKs, and LK MPPs (n 5 3). Data are mean 6 SEM. (B) The
expression of Jmjd6 in HSCs (LSKCD342CD1352), MPP1 (LSKCD341CD1352CD1501CD482), MPP2 (LSKCD341CD1352CD1501CD481), MPP3 (LSKCD341
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from BM were plated in XF-24 microplates precoated with
Cell-Tak (BD) at 250 000 cells per well in XF Base medium
supplemented with 10 mM glucose, pH 7.4. OCR was
measured 3 times every 6 minutes for basal value and after
each sequential addition of oligomycin (1 mM), FCCP (1 mM),
and rotenone and antimycin A (1 mM). Oxygen consumption
measurements were normalized to cell counts before and after
each assay.
Analysis of Jmjd6 expression in single-cell
hematopoietic populations
To assess the differences in Jmjd6 expression among populations,
we inspected 2 published single-cell data sets: a SMART-seq2
landscape of hematopoietic stem and progenitor populations29 and
a 103 landscape of LSK and Lin2Sca-12c-Kit1 (LK) populations.30
For both data sets, the corresponding bar plots of Jmjd6 expression
were generated upon computing the average and the standard
error of the mean (SEM) of the natural logarithm of the normalized
expression of Jmjd6 in each population or cluster. All analyses were
performed with the Scanpy python module.31
RNA-seq, GSEA, and differential splicing analysis
We assessed molecular consequences of Jmjd6 ablation in
hematopoietic stem and progenitor cells from young Jmjd6CTL
and Jmjd6cKO mice using RNA sequencing (RNA-seq). The use
of LSK cells, as opposed to highly purified HSCs, allowed us to
achieve a sufficient per-locus sequencing depth for robust global
expression and splicing analyses, while minimizing the number
of mice required. An average of 77.1 million 75-bp paired-end
reads was sequenced per sample. Alignment to the GRCm38
mouse genome was performed with HISAT2 version 2.1.0,32 and
read counts per gene were computed using the Rsubread package
version 2.0.1 in R. Gene differential expression, identified using
DESeq2 version 1.24, was ranked according to moderated t
statistics, which take into account variability between genes in
the ranking. Preranked genes were compared with gene lists in
the Hallmark subset of the MSigDB database version 7.0 using
gene set enrichment analysis (GSEA) software version 3.0 (http://
software.broadinstitute.org/gsea) with 1000 permutations and
default parameters. Splicing analysis was performed using DEXSeq
version 1.30.0, limma version 3.40.6, and QoRTs-JunctionSeq
version 1.14.0.
Results
JMJD6 is required for long-term HSC maintenance
under steady-state conditions
To determine the expression of Jmjd6 in mouse stem and
progenitor cells, we sorted LSK cells, LSKCD482CD1501 HSCs,
LSKCD482CD1502 multipotent progenitors (MPPs), primitive
hematopoietic progenitor cells (HPCs; ie, LSKCD481CD1502
HPC-1 and LSKCD481CD1501 HPC-2 populations), and LK
myeloid progenitors and performed reverse transcription quanti-
tative polymerase chain reaction. Jmjd6 was uniformly expressed
among these populations (Figure 1A), with higher expression in
MPPs and downregulation in LK myeloid progenitors. Addition-
ally, to assess the expression of Jmjd6 in further hematopoietic
compartments, we interrogated our SMART-seq2 single-cell expres-
sion data sets,29 and analysed Jmjd6 expression in long-term
HSC (LSKCD342CD1352), MPP1 (LSKCD341CD1352CD1501
CD482), MPP2 (LSKCD341CD1352CD1501CD481), and MPP3
(LSKCD341CD1352CD1502CD481) populations, lymphoid-
primed MPPs (LSKCD341CD1351), which correspond to the MPP4
population,33 common myeloid progenitor (CMP; LKCD341FcgRII/IIIlow),
granulocyte-macrophage progenitor (GMP; LKCD341FcgRII/IIIhigh),
and megakaryocyte-erythroid progenitor (MEP; LKCD342FcgRII/IIIlow)
compartments. These analyses revealed that Jmjd6 was expressed
rather uniformly across these populations (Figure 1B), with the
highest expression in MEPs and the lowest expression in the
MPP4 population. Finally, we used our 103 genomics single-
cell RNA-seq30 to analyze Jmjd6 expression in HSCs and
committed progenitor cell compartments, which revealed that
Jmjd6 was expressed comparably among these populations
(Figure 1C).
To determine the requirement for Jmjd6 in HSC maintenance
and multilineage hematopoiesis, we generated a floxed Jmjd6
allele in which exon 3 (encoding the catalytic domain) is flanked
by LoxP sites (supplemental Figure 1). We combined the Jmjd6fl
allele with Vav-iCre20 (Figure 1D; supplemental Figure 1) to generate
Jmjd6fl/fl;Vav-iCre (Jmjd6cKO) mice, in which Jmjd6 is specifically
deleted within the hematopoietic system. The absence of Jmjd6 from
the hematopoietic systemwas confirmed at the transcript and protein
levels (Figure 1E-F). Notably, Jmjd6 deletion had no impact on
murine viability, with Jmjd6cKO and control Jmjd6fl/fl (Jmjd6CTL) mice
born at normal Mendelian ratios, allowing us to investigate the
Figure 1. (continued) CD1352CD1502CD481), and lymphoid-primed multipotent progenitor (LMPP)/MPP4 (LSKCD341CD1351) populations, as well as in CMP
(LKCD341FcgRII/IIIlow), GMP (LKCD341FcgRII/IIIhigh), and MEP (LKCD342FcgRII/IIIlow) compartments, determined using single-cell SMART-seq2.29 Data are mean 6 SEM.
(C) Jmjd6 expression in HSCs and indicated committed progenitor cell compartments determined by 103 genomics single-cell RNA-seq.30 Bins represent clusters annotated
via marker genes. Data are mean 6 SEM. Ery, erythrocytes. (D) Genomic structure of the conditional Jmjd6 allele. Exon 3 is flanked by LoxP sites (red triangles). Following Cre-
mediated recombination, exon 3 is excised, resulting in a frameshift mutation and a non-sense–mediated decay. (E) Levels of Jmjd6 messenger RNA in Jmjd6fl/fl;Vav-iCre
(Jmjd6cKO) and control Jmjd6fl/fl (Jmjd6CTL) BM c-Kit1 cells (n 5 4). Data are mean 6 SEM. (F) Western blots for JMJD6 and b-actin from BM c-Kit1 cells from Jmjd6cKO and
Jmjd6CTL mice (n 5 3). (G) PB counts of white blood cells (WBCs), CD191B2201 B cells, CD41 and CD81 T cells, and CD11b1Gr-11 myeloid cells in 8- to 10-week-old
Jmjd6cKO and Jmjd6CTL mice (n 5 9-10). Data are mean 6 SEM. (H) Total BM cellularity of Jmjd6cKO and Jmjd6CTL 8- to 10-week-old mice (2 femurs and 2 tibias) (n 5 13-
16). Data are mean 6 SEM. (I) Total numbers of CMPs (LKCD341FcgRII/IIIlow), GMPs (LKCD341FcgRII/IIIhigh), MEPs (LKCD342FcgRII/IIIlow), and CLPs (Lin2Sca-1lowc-Kitlow
CD1271CD1351) in BM from 8- to 10-week-old Jmjd6cKO and Jmjd6CTL mice (n 5 13-16). Data are mean 6 SEM. (J-K) Total numbers of HSCs, MPPs, HPC-1, and HPC-2
populations in BM of Jmjd6cKO and Jmjd6CTL mice. (J) Eight- to 10-week-old mice (n 5 13-16). (K) Fifty-two–week-old mice (n 5 6-9). Data are mean 6 SEM. (L) Fold change
in HSC, MPP, HPC-1, and HPC-2 populations in 52-week-old vs 8- to 10-week-old Jmjd6cKO and Jmjd6CTL mice (n 5 6-13). (M) Percentage of DAPI2Annexin V1 and DAPI1
Annexin V1 cells in HSCs, MPPs, HPC-1, and HPC-2 populations in BM from 8- to 10-week-old Jmjd6cKO and Jmjd6CTL mice (n 5 6). Data are mean 6 SEM. (N) Percentage
of HSCs from 8- to 10-week-old Jmjd6cKO and Jmjd6CTL mice in the G0 (DAPI
2Ki672), G1 (DAPI
2Ki671), and G2/S/M (DAPI
1Ki671) phases of the cell cycle (n 5 6-7). Data
are mean 6 SEM. *P , .05, **P , .01, ***P , .001, ****P , .0001, Mann-Whitney U test.
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Figure 2. Loss of Jmjd6 significantly impacts recovery from hematopoietic injury. (A) Experimental design. Eight- to 12-week-old Jmjd6cKO and Jmjd6CTL mice were
administered 1 dose of 5-FU (250 mg/kg) via IV injection, and hematopoietic compartments were analyzed 10 and 14 days later. (B) Total BM cellularity (1 femur and 1 tibia)
of 5-FU–treated Jmjd6cKO and Jmjd6CTL mice (n 5 4-7) and Jmjd6CTL PBS-treated controls (n 5 2) at 10 and 14 days postinjection. Total cell numbers of B cells and myeloid
cells (C), LK cells (D), LSK cells (E), and HSCs, MPPs, and HPC-1 and HPC-2 populations (F) in BM from Jmjd6cKO and Jmjd6CTL mice 10 and 14 days following 5-FU
treatment (n 5 4-7). (G) Representative FACS profiles showing frequencies (6 SEM) of BM LSK, HSC, MPP, HPC-1, and HPC-2 cell populations from 5-FU–treated
Jmjd6cKO and Jmjd6CTL mice (n 5 4-7) and Jmjd6CTL PBS-treated controls (n 5 2) at 10 and 14 days postinjection. Data are mean 6 SEM. *P , .05, **P , .01,
Mann-Whitney U test.
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Figure 3. HSCs without JMJD6 fail to sustain multilineage hematopoiesis upon serial transplantation. (A) Experimental design. One hundred BM HSCs from 8- to
10-week-old Jmjd6cKO and Jmjd6CTL mice were transplanted into lethally irradiated syngeneic CD45.11/CD45.21 primary recipient mice together with 2 3 105 competitor
CD45.11 BM cells. After 16 weeks, 4 3 106 unfractionated BM cells from primary recipient mice were transplanted into lethally irradiated syngeneic CD45.11/CD45.21
secondary recipient mice together with 2 3 105 competitor CD45.11 BM cells. PB of primary and secondary recipient mice was analyzed every 4 weeks and hematopoietic
compartments were analyzed 16 weeks posttransplantation. (B) Percentage of CD45.21 cells in the overall PB compartment, as well as the myeloid, B-cell, and T-cell
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functional significance of Jmjd6 in adult HSC biology and multilineage
hematopoiesis.
PB analyses of Jmjd6cKO mice revealed a drastic reduction in the
numbers of white blood cells, B cells, and T cells, whereas the
numbers of erythrocytes andmyeloid cells were unaffected (Figure 1G;
supplemental Figure 2A). BM and spleens from Jmjd6cKO mice
exhibited normal total cellularity and largely unaffected differenti-
ated cell counts (Figures 1H; supplemental Figure 2B-C). Notably,
BM GMPs and common lymphoid progenitors (CLPs) were
markedly decreased, whereas CMPs and MEPs were unchanged
(Figure 1I). Strikingly, although Jmjd6-deficient BM cells displayed
normal differentiation in CFC assays, they failed to form secondary
colonies after replating (supplemental Figure 2D). Thus, loss of
JMJD6 has a minimal impact on myeloid differentiation, but depletes
CLPs and compromises lymphoid lineage output under steady-
state conditions.
Having discovered a decrease in GMPs and CLPs upon Jmjd6
deletion, as well as failure of colony formation upon replating,
we next investigated the impact of Jmjd6 deficiency at the top of
the hematopoietic differentiation hierarchy. Eight- to 12-week-old
Jmjd6cKO mice displayed a significant depletion of HSC and MPP
cell pools compared with Jmjd6CTL mice (Figure 1J; supplemental
Figure 2E). Furthermore, to test the impact of Jmjd6 deletion on
long-term HSC maintenance under steady-state conditions, we
aged Jmjd6cKO and Jmjd6CTL mice for 52 weeks and found that
aged Jmjd6cKO mice exhibited a more pronounced HSC loss
than did young Jmjd6cKO mice, relative to age-matched controls
(Figure 1K-L; supplemental Figure 3). Consistent with an increase
in HSC numbers upon physiological aging,34 we found that the
HSC pool in aged Jmjd6CTL mice expanded 4.24-fold vs young
animals, whereas the HSC pool in Jmjd6cKO mice expanded only
2.12-fold (Figure 1L). Notably, despite a marked decrease in HSC
numbers, aged Jmjd6cKO mice did not display any other hemato-
poietic defects (supplemental Figure 3B-D), suggesting the activation
of compensatory mechanisms upon aging to bypass phenotypes
(including a decrease in CLPs and GMPs, and lymphoid defects)
observed in young Jmjd6cKO mice. Taken together, JMJD6 is essential
for long-term cell-autonomous maintenance of the HSC pool during
unperturbed hematopoiesis.
HSCs lacking Jmjd6 have normal survival rate and
remain quiescent
Given that HSC depletion may result from an increase in cell death
or a loss of HSC quiescence,35,36 we investigated whether
the reduction in HSCs upon Jmjd6 deletion is associated with
increased apoptosis or decreased quiescence. To determine the
rate of cell death, we analyzed primitive hematopoietic compart-
ments using DAPI and Annexin V. The percentages of DAPI2
Annexin V1 (early apoptotic) or DAPI1Annexin V1 (late apoptotic)
cells were comparable between Jmjd6CTL and Jmjd6cKO mice
(Figure 1M). Furthermore, to determine the cell cycle status of
Jmjd6-deficient HSCs, we used Ki-67 and DAPI staining, which did
not reveal any differences in the quiescence of Jmjd6CTL and
Jmjd6cKO HSCs (Figure 1N). Therefore, HSC depletion upon Jmjd6
loss is unlikely to result from increased HSC apoptosis or their loss
of quiescence.
Jmjd6 deletion delays hematopoietic cell recovery
following myeloablation
Given the progressive loss of Jmjd6-deficient HSCs, we next
investigated their regenerative capacity upon hematopoietic injury.
Young 8- to 12-week-old Jmjd6CTL and Jmjd6cKO mice were
administered a single dose of 5-FU and analyzed 10 and 14 days
postinjection (Figure 2A). At day 10 following 5-FU treatment,
Jmjd6cKO mice displayed a marked decrease in total BM cellularity
and BM differentiated cells (Figure 2B-C), as well as near-complete
ablation of myeloid progenitors (Figure 2D), HSCs, and primitive
progenitor cell compartments (Figure 2E-G) compared with Jmjd6CTL
mice. Analyses at day 14 posttreatment revealed a decrease
in differentiated cell numbers in Jmjd6cKO mice (Figure 2B-C) vs
Jmjd6CTL mice; however, the difference was notably less marked
than at day 10 posttreatment. Strikingly, at day 14 posttreatment,
we observed a robust recovery of the LK, LSK, HSC, HPC-1, and
HPC-2 cell compartments in Jmjd6cKO mice, whereas the recovery
of MPP cells remained defective (Figure 2D-G). Overall, based on
these data, we conclude that JMJD6 deficiency delays the recovery
of hematopoietic cells at the primitive and differentiated hierarchical
levels following myeloablation.
JMJD6 is essential for HSC maintenance upon
serial transplantation
Considering the significant HSC depletion in steady-state con-
ditions, as well as the delay in the regeneration of Jmjd6-deficient
HSCs upon hematopoietic injury, we next tested the multilineage
reconstitution capacity of Jmjd6cKO HSCs upon serial trans-
plantation (Figure 3A). First, we competitively transplanted HSCs
from young Jmjd6cKO and Jmjd6CTL mice into lethally irradiated
primary recipients and found that Jmjd6-deficient HSCs displayed
reduced donor-derived chimerism compared with control HSCs
(Figure 3B). Moreover, Jmjd6cKO HSCs retained their myeloid-
reconstitution capacity but lost their lymphoid lineage–differentiation
potential, suggesting a myeloid bias (Figure 3B). Notably, although
Jmjd6cKO HSC and MPP populations were reduced under steady-
state conditions (Figure 1J), Jmjd6cKO HSCs contributed to the
HSC and primitive progenitor cell compartments of primary
recipients in a comparable manner to Jmjd6CTL HSCs (Figure 3C).
Strikingly, however, secondary transplantation unveiled a dramatic
failure of Jmjd6-deficient HSCs to repopulate short- and long-term
multilineage hematopoiesis, with Jmjd6cKO HSCs unable to con-
tribute to the PB compartment, and a significant reduction in
Figure 3. (continued) compartments, in primary recipient mice (n 5 2 per genotype; 4-5 recipients per group). (C) Percentage of CD45.21 cells within the total BM,
LK, LSK, HSC, MPP, HPC-1, and HPC-2 compartments of primary recipient mice 16 weeks after transplantation (n 5 2 per genotype; 4-5 recipients per group).
(D) Percentage of CD45.21 cells in the overall PB compartment, as well as the myeloid, B-cell, and T-cell compartments, in secondary recipient mice (n 5 2 per
genotype; 4-5 recipients per group). (E) Percentage of CD45.21 cells within the total BM, LK, LSK, HSC, MPP, HPC-1, and HPC-2 compartments of secondary
recipient mice 16 weeks after transplantation (n 5 2 per genotype; 4-5 recipients per group). Data represent mean 6 SEM. *P , .05, **P , .01, ***P , .001,
****P , .0001, Mann-Whitney U test.
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Figure 4. Jmjd6-deficient HSPCs display molecular signatures of functional HSC decline, which can be rescued by removing ROS. (A) GSEA showing
upregulated and downregulated pathways in LSKs from 8- to 12-week-old Jmjd6cKO mice compared with LSKs from 8- to 12-week-old Jmjd6CTL mice (n 5 4). (B) GSEA plots
for stabilization of p53, apoptosis via p21/p53 axis, and OXPHOS based on analysis of gene expression changes, using Jmjd6cKO LSK cells for upregulated pathways (n 5 4).
(C) OCR in Jmjd6cKO and Jmjd6CTL BM c-Kit1 cells under basal conditions and maximal OCR. Maximal OCR was achieved by the sequential addition of oligomycin (ATPase
inhibitor), FCCP (mitochondrial uncoupler), and rotenone and antimycin A (complex I and III inhibitors, respectively) (n 5 3). (D) ROS levels in c-Kit1 Jmjd6cKO and Jmjd6CTL
BM cells after a 1-hour incubation with CellROX reagent. Data represent mean fluorescence intensity (MFI) (n 5 8-9). (E) Experimental design. BM cells from 8- to 10-week-
old Jmjd6cKO and Jmjd6CTL mice were placed in CFC assays with 5 mM NAC or PBS control. CFC1 colonies were counted and scored 10 days after plating and replated
into CFC2. CFC2 colonies were counted after 10 days in culture. (F) CFC1. G, granulocyte; GEMM, granulocyte, erythroid, macrophage, or megakaryocyte; GM, granulocyte
and monocyte/macrophage; M, monocyte/macrophage; (n 5 4). (G) CFC 2 (n 5 4). (H) Experimental design. Eight- to 12-week-old Jmjd6cKO and Jmjd6CTL mice were
administered a daily dose of NAC (100 mg/kg) via intraperitoneal injection, as well as in drinking water (1 mg/mL). Hematopoietic compartments were analyzed following
10 days of treatment. Total cell numbers of HSCs (I) and CLPs (J) in BM from Jmjd6cKO and Jmjd6CTL mice after 10 days of NAC treatment (n 5 4-5). Data are mean 6 SEM.
*P , .05, **P , .01. NS, not significant.
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the contribution to BM primitive and progenitor compartments
compared with Jmjd6CTL HSCs (Figure 3D-E). Therefore, JMJD6 is
an essential regulator of HSC self-renewal and posttransplantation
multilineage hematopoiesis.
JMJD6 suppresses OXPHOS and ROS generation to
control hematopoiesis
To mechanistically understand the failure of Jmjd6-deficient HSCs
upon serial transplantation, we examined the molecular signature
of Jmjd6-deficient LSK cells. Although differential gene expres-
sion analysis identified a number of individual deregulated genes
(supplemental Figure 4), GSEA indicated a broader upregulation
of processes detrimental to HSCs, including p53 activity35,37
(which is known to be directly repressed by JMJD67,17), G1/S
and G2/M checkpoints, OXPHOS,
38 mTORC1 signaling,39 protein
synthesis,40 and E2F signaling41 (Figure 4A-B). Given that
suppression of OXPHOS is essential for HSC self-renewal, and
its upregulation devastates HSC functions,38 we validated the
impact of Jmjd6 deletion on OXPHOS using a Seahorse XF
Analyzer. We found that the basal and maximal OCRs were
significantly increased in Jmjd6-deficient cells (Figure 4C). Thus,
Jmjd6 deletion results in upregulation of multiple pathways, including
activation of OXPHOS, whose excessive activation is known to
have detrimental consequences to HSCs.
Given that elevated mitochondrial respiration frequently contributes
to the formation of ROS,38,42 we investigated whether enhanced
OXPHOS in Jmjd6-deficient cells results in increased ROS
generation. Using CellROX to detect and quantify ROS levels,
we discovered that c-Kit1 cells from Jmjd6cKO mice had significantly
increased levels of ROS compared with control cells (Figure 4D).
Given that elevated ROS have detrimental consequences to
hematopoietic cells,42,43 we next tested whether the antioxidant
NAC could alleviate the hematopoietic phenotypes resulting from
Jmjd6 deficiency. To investigate this, we serially plated BM cells
from Jmjd6CTL and Jmjd6cKOmice into CFC assays, in the presence or
absence of NAC (Figure 4E). As expected, Jmjd6CTL and Jmjd6cKO
cells efficiently generated primary colonies in control and NAC-
containing methylcellulose cultures (Figure 4F). However, al-
though Jmjd6-deficient cells failed to replate in the absence
of NAC, strikingly, Jmjd6-deficient cells incubated with NAC
efficiently produced colony numbers that were comparable to
control cells (Figure 4G). Finally, to determine the significance of
elevated ROS upon Jmjd6 deletion in vivo, we treated Jmjd6CTL
and Jmjd6cKO mice with NAC for 10 days (Figure 4H). Signif-
icantly, we discovered that Jmjd6cKO mice treated with NAC no
longer displayed reduced numbers of HSC and CLP cell populations
(Figure 4I-J). Taken together, we conclude that elevated ROS in Jmjd6-
deficient cells is causal for their failure to generate hematopoietic
colonies upon replating, as well as contributing to reduced HSC and
CLP numbers in Jmjd6cKO mice in vivo.
JMJD6 does not regulate messenger RNA splicing
in HSPCs
Finally, JMJD6 is known to catalyze hydroxylation of splicing
regulators, including U2A65 (2AF2), and has been shown to
regulate splicing in vivo in developing tissues and the thymus.44,45
We therefore asked to what extent Jmjd6 deletion impacts alternative
splicing. In spite of substantial RNA-seq coverage, only 7 transcripts
showed an effect in LSK cells (supplemental Figure 5). This result
indicates that JMJD6 is unlikely to function as a major regulator of
alternative splicing in HSCs and progenitors.
Discussion
Despite extensive biochemical studies, the functional significance
of JMJD6 in normal adult tissues remains poorly understood. JMJD6
is a predominantly nuclear protein, which is reported to regulate
transcription and messenger RNA splicing.11,13,14 At the molecular
level, JMJD6 catalyzes hydroxylation of lysine residues of multi-
ple substrates, including p53,7,17 pVHL,7,9,10 ERa,13 and splicing
regulators, including U2AF65.12,44 Our analyses revealed that loss
of JMJD6 results in HSC depletion and functional failure of HSCs to
sustain self-renewal and hematopoietic regeneration. Furthermore,
loss of Jmjd6 exposes HSCs to molecular vulnerabilities, upregulat-
ing multiple pathways whose suppression is essential for normal
HSC functions, including OXPHOS.38 Consistent with increased
mitochondrial OXPHOS upon Jmjd6 deletion, which predisposes
to ROS generation,38,42 ROS were causal, at least in part, for HSC
and CLP depletion resulting from Jmjd6 loss, implying that, under
physiological conditions, JMJD6 may function to repress OXPHOS-
generated ROS to control hematopoiesis. Furthermore, consistent
with direct suppression of p53 by JMJD6,7,17 we found that Jmjd6-
deficient cells upregulated p53-related signatures, whose activation
promotes HSC loss.35,37We also found that Jmjd6 deficiency results
in upregulation of other pathways whose activity is known to deplete
or exhaust HSCs, including mTORC1 signaling,39 protein synthe-
sis,40 and E2F downstream pathway.41 Notably, although our findings
reveal JMJD6 as a suppressor of multiple pathways, whose excessive
activation promotes HSC failure, the mechanisms through which
JMJD6 functions in this context remain an open question, meriting
further investigations. Finally, we revealed that JMJD6 is unlikely to be
a major splicing regulator in HSCs. Rather, JMJD6 functions to
promote the long-term maintenance of HSCs, their regenerative
capacity, and self-renewal potential by restraining multiple pathways,
including OXPHOS-mediated ROS generation, whose strict control
is essential for their integrity.
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